The analysis in this research service is based on the following:
Information collected through discussions with market participants and from secondary sources, including pharmaceutical companies and medical device companies involved in drug delivery systems, as well as other Web sites and credible sources
Public announcements and plans by key market leaders, suppliers, new entrants, and others
Frost & Sullivan’s published research and market and technology expertise
All market figures and shares listed in the research are Frost & Sullivan's assessment based on its research.
For Market Engineering research, Frost & Sullivan utilises tried and tested marketing techniques to provide structure to the research and an easy format to compare results across different countries and markets. This project was carried out using primary (telephone) and secondary (published and online material) research as the principle methods of data gathering. The focus of the interviews for this project was primarily the following types of respondents:
Key regulatory bodies
Frost & Sullivan published research services
Decision support databases
Country industry forecasts
Annual reports published by companies
About this report
The growing population base, driven by increased life expectancy and domestic investment, is expected to continuously accelerate GDP in Malaysia. Significant growth of healthcare expenditure is expected in the country to facilitate the improvement of medical access and provide companies with revenue-earning opportunities from 2015. Positive macroeconomic and healthcare market trends are expected to fast-track the pharmaceutical market in Malaysia. The study explores the broad competitive landscape, demand dynamics, and regulatory environment that investors must consider while entering this pharmaceutical market.
Electronic Access - Site License Fulfilled By Publisher
Electronic Access - Global site License Fulfilled By Publisher